CoChat
Sign Up
Cited by 58

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Cellular Prion Protein as a Receptor of Toxic Amyloid-β42 Oligomers Is Important for Alzheimer’s Disease

Zhang, Yuan, Zhao, Yanfang, Zhang, Lei, Yu, Wanpeng, Wang, Yu, Chang, Wenguang·2019·Frontiers in Cellular Neuroscience
DOI 10.3389/fncel.2019.00339PMC PMC6682659
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fncel.2019.00339

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 60

  1. Abu Rumeileh, 2017, Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and Abeta42 in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer’s Disease with Emphasis on Atypical Disease Variants., J. Alzheimer’s Dis., 55, 1471, 10.3233/JAD-160740 · DOI
  2. Barry, 2011, Alzheimer’s disease brain-derived amyloid-beta-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein., J. Neurosci., 31, 7259, 10.1523/JNEUROSCI.6500-10.2011 · DOI · Paper page
  3. Baumann, 2007, Lethal recessive myelin toxicity of prion protein lacking its central domain., EMBO J., 26, 538, 10.1038/sj.emboj.7601510 · DOI
  4. Beland, 2014, Abeta induces its own prion protein N-terminal fragment (PrPN1)-mediated neutralization in amorphous aggregates., Neurobiol. Aging., 35, 1537, 10.1016/j.neurobiolaging.2014.02.001 · DOI
  5. Benilova, 2012, The toxic Abeta oligomer and Alzheimer’s disease: an emperor in need of clothes., Nat. Neurosci., 15, 349, 10.1038/nn.3028 · DOI · Paper page
  6. Brody, 2018, Synaptotoxic signaling by amyloid beta oligomers in Alzheimer’s disease through prion protein and mGluR5., Adv. Pharmacol., 82, 293, 10.1016/bs.apha.2017.09.007 · DOI
  7. Brouillette, 2014, The effects of soluble Abeta oligomers on neurodegeneration in Alzheimer’s disease., Curr. Pharm. Design., 20, 2506, 10.2174/13816128113199990498 · DOI
  8. Carulla, 2011, Neuroprotective role of PrPC against kainate-induced epileptic seizures and cell death depends on the modulation of JNK3 activation by GluR6/7-PSD-95 binding., Mol. Biol. Cell., 22, 3041, 10.1091/mbc.E11-04-0321 · DOI
  9. Caughey, 2003, Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders., Annu. Rev. Neurosci., 26, 267, 10.1146/annurev.neuro.26.010302.081142 · DOI · Paper page
  10. Chen, 2010, Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues., J. Biol. Chem., 285, 26377, 10.1074/jbc.M110.145516 · DOI
  11. Chung, 2010, Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer’s disease model mouse., BMC Neurosci., 11, 10.1186/1471-2202-11-130 · DOI · Paper page
  12. Cox, 2019, Anti-PrP(C) antibody rescues cognition and synapses in transgenic alzheimer mice., Ann. Clin. Transl. Neurol., 6, 554, 10.1002/acn3.730 · DOI · Paper page
  13. Da Costa Dias, 2014, The 37kDa/67kDa laminin receptor acts as a receptor for Abeta42 internalization., Sci. Rep., 4, 10.1038/srep05556 · DOI
  14. Di Lazzaro, 2018, Emergence of neurophysiological biomarkers of Alzheimer disease., J. Neurol.Neurosurg.Psychiatry, 89, 10.1136/jnnp-2018-318867 · DOI
  15. Didonna, 2015, Characterization of four new monoclonal antibodies against the distal N-terminal region of PrP(c)., PeerJ., 3, 10.7717/peerj.811 · DOI
  16. Dohler, 2014, High molecular mass assemblies of amyloid-beta oligomers bind prion protein in patients with Alzheimer’s disease., Brain J. Neurol., 137, 873, 10.1093/brain/awt375 · DOI
  17. Ermonval, 2003, Evolving views in prion glycosylation: functional and pathological implications., Biochimie., 85, 33, 10.1016/s0300-9084(03)00040-3 · DOI
  18. Figueiredo, 2013, Memantine rescues transient cognitive impairment caused by high-molecular-weight abeta oligomers but not the persistent impairment induced by low-molecular-weight oligomers., J. Neurosci., 33, 9626, 10.1523/JNEUROSCI.0482-13.2013 · DOI
  19. Fluharty, 2013, An N-terminal fragment of the prion protein binds to amyloid-beta oligomers and inhibits their neurotoxicity in vivo., J. Biol. Chem., 288, 7857, 10.1074/jbc.M112.423954 · DOI
  20. Freir, 2011, Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites., Nat. Commun., 2, 10.1038/ncomms1341 · DOI
  21. Gimbel, 2010, Memory impairment in transgenic Alzheimer mice requires cellular prion protein., J. Neurosci., 30, 6367, 10.1523/JNEUROSCI.0395-10.2010 · DOI · Paper page
  22. Gouras, 2015, beta-Amyloid peptides and amyloid plaques in Alzheimer’s disease., Neurotherapeutics, 12, 3, 10.1007/s13311-014-0313-y · DOI
  23. Haas, 2016, Oligomers of Amyloid beta Prevent Physiological Activation of the Cellular Prion Protein-Metabotropic Glutamate Receptor 5 Complex by Glutamate in Alzheimer Disease., J. Biol. Chem., 291, 17112, 10.1074/jbc.M116.720664 · DOI · Paper page
  24. Haass, 2007, Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide., Nat. Rev. Mol. Cell Biol., 8, 101, 10.1038/nrm2101 · DOI · Paper page
  25. Hu, 2014, mGlu5 receptors and cellular prion protein mediate amyloid-beta-facilitated synaptic long-term depression in vivo., Nat. Commun., 5, 10.1038/ncomms4374 · DOI
  26. Jackson, 2001, Location and properties of metal-binding sites on the human prion protein., Proc. Natl. Acad. Sci. U.S.A., 98, 8531, 10.1073/pnas.151038498 · DOI
  27. Jeong, 2015, Neuroprotective effect of cellular prion protein (PrPC) is related with activation of alpha7 nicotinic acetylcholine receptor (alpha7nAchR)-mediated autophagy flux., Oncotarget, 6, 24660, 10.18632/oncotarget.4953 · DOI
  28. Kayed, 2013, Molecular mechanisms of amyloid oligomers toxicity., J. Alzheimer’s Dis., S67
  29. Kudo, 2012, Cellular prion protein is essential for oligomeric amyloid-beta-induced neuronal cell death., Hum. Mol. Genetics., 21, 1138, 10.1093/hmg/ddr542 · DOI
  30. Larson, 2012, The complex PrP(c)-Fyn couples human oligomeric Abeta with pathological tau changes in Alzheimer’s disease., J. Neurosci., 32, 16857a, 10.1523/JNEUROSCI.1858-12.2012 · DOI
  31. Li, 2007, Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105-125., EMBO J., 26, 548, 10.1038/sj.emboj.7601507 · DOI
  32. Li, 2018, Pyk2 is a novel tau tyrosine kinase that is regulated by the tyrosine kinase fyn., J. Alzheimer’s Dis., 64, 205, 10.3233/JAD-180054 · DOI · Paper page
  33. Onodera, 2017, Dual role of cellular prion protein in normal host and Alzheimer’s disease., Proc. Japan Acad. Ser. BPhys. Biol. Sci., 93, 155, 10.2183/pjab.93.010 · DOI
  34. Pinnock, 2016, LRP/LR antibody mediated rescuing of amyloid-beta-induced cytotoxicity is dependent on PrPc in Alzheimer’s disease., J. Alzheimer’s Dis., 49, 645, 10.3233/JAD-150482 · DOI
  35. Purro, 2018, Prion protein as a toxic acceptor of amyloid-beta oligomers., Biol. psychiatry., 83, 358, 10.1016/j.biopsych.2017.11.020 · DOI
  36. Resenberger, 2011, The cellular prion protein mediates neurotoxic signalling of beta-sheet-rich conformers independent of prion replication., EMBO J., 30, 2057, 10.1038/emboj.2011.86 · DOI
  37. Rushworth, 2013, Prion protein-mediated toxicity of amyloid-beta oligomers requires lipid rafts and the transmembrane LRP1., J. Biol. Chem., 288, 8935, 10.1074/jbc.M112.400358 · DOI
  38. Saijo, 2011, Unaltered prion protein expression in Alzheimer disease patients., Prion., 5, 109, 10.4161/pri.5.2.16355 · DOI
  39. Sakono, 2010, Amyloid oligomers: formation and toxicity of Abeta oligomers., FEBS J., 277, 1348, 10.1111/j.1742-4658.2010.07568.x · DOI
  40. Salazar, 2017, Cellular prion protein as a receptor for amyloid-beta oligomers in Alzheimer’s disease., Biochem. Biophys. Res. Commun., 483, 1143, 10.1016/j.bbrc.2016.09.062 · DOI
  41. Schwarze-Eicker, 2005, Prion protein (PrPc) promotes beta-amyloid plaque formation., Neurobiol. Aging., 26, 1177, 10.1016/j.neurobiolaging.2004.10.004 · DOI
  42. Scott-McKean, 2016, Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Abeta oligomers: implications for novel therapeutic strategy in Alzheimer’s disease., Neurobiol. Dis., 91, 124, 10.1016/j.nbd.2016.03.001 · DOI
  43. Selkoe, 2011, Alzheimer’s disease., Cold Spring Harb. Perspect. Biol., 3, 10.1101/cshperspect.a004457 · DOI
  44. Singh, 2015, Molecular mechanism of the misfolding and oligomerization of the prion protein: current understanding and its implications., Biochemistry, 54, 4431, 10.1021/acs.biochem.5b00605 · DOI
  45. Takahashi, 2011, Accumulation of cellular prion protein within dystrophic neurites of amyloid plaques in the Alzheimer’s disease brain., Neuropathology, 31, 208, 10.1111/j.1440-1789.2010.01158.x · DOI
  46. Taylor, 2006, The prion protein and lipid rafts., Mol. Membr. Biol., 23, 89, 10.1080/09687860500449994 · DOI
  47. Taylor, 2005, Assigning functions to distinct regions of the N-terminus of the prion protein that are involved in its copper-stimulated, clathrin-dependent endocytosis., J. Cell Sci., 118, 5141, 10.1242/jcs.02627 · DOI
  48. Um, 2012, Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons., Nat. Neurosci., 15, 1227, 10.1038/nn.3178 · DOI
  49. Velayos, 2009, The cellular prion protein and its role in Alzheimer disease., Prion, 3, 110, 10.4161/pri.3.2.9135 · DOI
  50. Vergara, 2015, Role of PrP(C) expression in tau protein levels and phosphorylation in Alzheimer’s disease evolution., Mol. Neurobiol., 51, 1206, 10.1007/s12035-014-8793-7 · DOI
  51. Viles, 1999, Copper binding to the prion protein: structural implications of four identical cooperative binding sites., Proc Natl. Acad. Sci.U.S.A., 96, 2042, 10.1073/pnas.96.5.2042 · DOI
  52. Whitehouse, 2010, Prion protein is reduced in aging and in sporadic but not in familial Alzheimer’s disease., J. Alzheimer’s Dis., 22, 1023, 10.3233/JAD-2010-101071 · DOI
  53. Wildburger, 2017, Diversity of amyloid-beta proteoforms in the Alzheimer’s disease brain., Sci. Rep., 7, 10.1038/s41598-017-10422-x · DOI · Paper page
  54. Wiseman, 2015, The glycosylation status of PrPC is a key factor in determining transmissible spongiform encephalopathy transmission between species., J. Virol., 89, 4738, 10.1128/JVI.02296-14 · DOI
  55. Wisniewski, 2011, Submicromolar Abeta42 reduces hippocampal glutamate receptors and presynaptic markers in an aggregation-dependent manner., Biochim. Biophys. Acta., 1812, 1664, 10.1016/j.bbadis.2011.09.011 · DOI
  56. Wuthrich, 2001, Three-dimensional structures of prion proteins., Adv. Protein Chem., 57, 55, 10.1016/s0065-3233(01)57018-7 · DOI
  57. Zafar, 2017, Prion protein interactome: identifying novel targets in slowly and rapidly progressive forms of Alzheimer’s disease., J. Alzheimer’s Dis., 59, 265, 10.3233/JAD-170237 · DOI
  58. Zhao, 2010, Inhibition of calcineurin-mediated endocytosis and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid beta oligomer-induced synaptic disruption., J. Biol. Chem., 285, 7619, 10.1074/jbc.M109.057182 · DOI · Paper page
  59. Zou, 2011, Amyloid-beta42 interacts mainly with insoluble prion protein in the Alzheimer brain., J. Biol. Chem., 286, 15095, 10.1074/jbc.M110.199356 · DOI
  60. Zuegg, 2000, Molecular dynamics simulation of human prion protein including both N-linked oligosaccharides and the GPI anchor., Glycobiology, 10, 959, 10.1093/glycob/10.10.959 · DOI

Cited by

Sorted by citations

Metadata

Authors
Zhang, Y., Zhao, Y., Zhang, L., Yu, W., Wang, Y., & Chang, W.
Venue
Frontiers in Cellular Neuroscience
Publisher
Frontiers Media SA
Published
2019-07-30
Volume
13
ISSN
1662-5102
DOI
10.3389/fncel.2019.00339
PMC
PMC6682659
Cited by
58
References
7
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review